Alkermes plc
ALKS
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $7.7B
$46.10
▼ -1.66%
P/E
120.37
Mkt Cap
$7.7B
52-Wk Range
$25.17–$55.67
52-Week Range
$25.17 - $55.67
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 62.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary long-acting injectable technology platform with established market presence and patient loyalty
- Strategic partnerships with Janssen Pharmaceutica providing manufacturing, distribution, and commercialization support
- Diversified product portfolio spanning psychiatry, addiction medicine, neurology, and oncology reducing revenue concentration risk
- Experienced management team with deep biopharmaceutical expertise and regulatory track record
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Profitability at risk
Strong operating leverage (17% operating margin)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+8.6% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ALKS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $0.70 vs -$0.03 consensus (+2650.1% surprise). Revenue of $496.0M vs $457.4M expected (+8.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2650.1%
Revenue trend · last 8Q
—
+14%
-13%
-2%
+4%
-11%
+28%
+27%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$378.1M
$430.0M
$306.5M
$390.7M
$394.2M
$384.5M
$392.9M
$496.0M
Margins · last 8Q
Gross
0.0%
Operating
3.7%
Profit
0.1%
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
29%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 30, 2026
vs Industry
How ALKS stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related